NEW SCIENCE VENTURES - Key Persons

Job Titles:

• Associate
• Member of the Investment Team
• Partner

Andrew Abrams joined New Science Ventures as an Associate in September 2016 and became a Partner in July 2020. He was formerly an Associate in J.P. Morgan's healthcare investment banking practice in London, where he focused on mergers and acquisitions and equity transactions in Europe and the U.S. He advised a wide array of clients spanning the biotechnology, pharmaceutical, medical device, diagnostic and service sub-sectors. Andrew serves on the Board of Directors for Morrow, Novadip Biosciences, Ovizio, Trellis Bioscience and Vimalan Biosciences and formerly served on the Board of Directors of Paradigm Diagnostics (acquired by Exact Sciences in March 2020). He holds B.A., M.A. and M.Sci. degrees in Natural Sciences and Biochemistry from the University of Cambridge. He also holds an M.B.A. from Harvard Business School. Andrew was based in our New York office from 2016-2019 followed by a year in our San Diego therapeutics incubator. He is currently based in our London office.

Job Titles:

• Chief Financial Officer
• Member of the Finance Team
• Partner
• Finance Team

Brenda joined New Science Ventures in October 2010 and currently serves as Chief Financial Officer. Prior to joining New Science Ventures she was a fund controller at Cerberus Capital, managing multiple hedge funds, private equity and distressed funds with AUM over $8B. Prior to Cerberus, she was a Controller and Vice President at Citigroup Alternative Investments responsible for all financial functions, consolidation, reporting and compliance. Brenda started her career at Eisner, a mid size public accounting firm where she managed numerous audit engagements for financial services clients. She received a B.A. degree in Accounting and Information Systems from Queens College and is a Certified Public Accountant in the state of New York.

Job Titles:

• Member of the Investment Team
• Non - Executive Director
• Partner
• Senior Advisor

Jean-Pierre Bizet joined New Science Ventures as a Partner and Senior Advisor in February 2015. Jean-Pierre is a non-executive director on several company boards, and a professor of strategy at Université Libre de Bruxelles. Previously, he was CEO of D'Ieteren, a listed diversified company in various distribution segments of the automobile sector. Until 2002, Jean-Pierre was CEO of GIB Group, a diversified retail group. Prior to GIB, Jean-Pierre was a Director at McKinsey & Company, serving European clients from the Paris Office, and serving as a co-leader of the firm's Change Management practice. Jean-Pierre holds a PhD in Applied Economics from U. of Brussels, an M.B.A. from Harvard Business School, and a M.S. from Solvay Brussels School of Economics & Management.

Job Titles:

• Controller
• Member of the Finance Team

Jonny He joined NSV in June 2016 and currently serves as Controller. He was formerly a private equity supervisor in HedgeServ, Inc. Prior to HedgeServ, he was an Assistant Vice President at J.P. Morgan in the Private Equity & Real Estate Services group managing a team that provides accounting and financial reporting services. Jonny started his career in BDO Seidman as an assurance associate. Jonny received a BS in Accounting from Brooklyn College and holds his CPA license in the state of New York. He is also a member of the American Institute of Certified Public Accountants.

Job Titles:

• Member of the Investment Team
• Partner
• Senior Advisor
• in 2017 As a Senior Advisor

Raju Mohan joined New Science Ventures in 2017 as a Senior Advisor to the firm. He has over 25 years of drug discovery and development experience in pharma and biotech. Raju has co-founded multiple biotech companies, including Akarna Therapeutics (acquired by Allergan), Ralexar Therapeutics, Escalier Biosciences, Oppilan Pharma and Ventyx Biosciences. Raju founded and served as President of Anayaderm (acquired by Ralexar) and has previously served as the Vice President of Chemistry at X-Ceptor (acquired by Exelixis) and Vice-President and site-head for Exelixis' San Diego site. He has also held increasingly senior positions at Berlex Biosciences, a subsidiary of Bayer/Schering AG. Raju is responsible for the discovery of multiple small-molecule compounds that have entered the clinic including one currently in Phase 3 trials. He has published extensively in peer-reviewed journals and is an inventor on 50 issued US patents. Raju received his Ph.D. in Chemistry from the University of Illinois at Urbana-Champaign and his Master's degree from the Indian Institute of Technology.

Job Titles:

• Co - Founder
• Managing Partner
• Member of the Investment Team

Somu Subramaniam is the co-founder and Managing Partner of New Science Ventures. Somu serves on the Board of Directors of Achronix Semiconductor Corporation, Antevia Networks, Avari Wireless, Ferric, Inc, Oxyrane, Pakal Technologies, Paragraf, Resolve Therapeutics, Ventyx Biosciences, Inc and Vimalan Biosciences, Inc. Somu has also served on the Boards of Dezima Pharma (acquired by Amgen), Ception Therapeutics (acquired by Cephalon), BioVex (acquired by Amgen), Lightwire (acquired by Cisco), K2M (acquired by Welsh Carson) and Akarna Therapeutics (acquired by Allergan). Prior to founding NSV, Somu was a director at McKinsey & Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries. At McKinsey, Somu was leader of the Strategy Practice, the Technology Practice, the Biotechnology Group, and the Healthcare Practice. He also served on the firm's Investment Committee and led its Equity Portfolio Committee. Somu holds a B.Tech. degree from the Indian Institute of Technology and an M.B.A. from Harvard Business School.

Job Titles:

• Co - Founder
• Member of the Investment Team
• Partner

Tom Lavin is a co-founder and Partner of New Science Ventures. He serves on the Board of Directors for Achronix Semiconductor Corporation, Dali Wireless, Interlink AI and Phase Four, Inc. and is an observer on the boards of Juventas Therapeutics and Vorago. He formerly served on the Board of Celleration (acquired by Aliqua). Prior to NSV, he was a senior professional in finance and investment banking for over 30 years. Tom has extensive experience in private and public equity and debt transactions, mergers and acquisitions and financial restructurings in the U.S. and abroad. He was head of real estate investment banking at First Boston and Smith Barney and head of commercial mortgage lending at MetLife. Tom holds an A.B. degree in Government from Wesleyan University and an M.B.A. from Harvard Business School.